Cited 2 times in
Effects of Dihydropyridines on the Motor and Cognitive Outcomes of Patients with Parkinson's Disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 손영호 | - |
dc.contributor.author | 유한수 | - |
dc.contributor.author | 이양현 | - |
dc.contributor.author | 이필휴 | - |
dc.contributor.author | 정석종 | - |
dc.contributor.author | 나한규 | - |
dc.contributor.author | 백경원 | - |
dc.date.accessioned | 2024-01-03T01:24:25Z | - |
dc.date.available | 2024-01-03T01:24:25Z | - |
dc.date.issued | 2023-05 | - |
dc.identifier.issn | 0885-3185 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/197547 | - |
dc.description.abstract | Background: Dihydropyridines (DHPs) may have neuroprotective effects against Parkinson's disease (PD). Objective: This study investigated the effects of DHPs on nigrostriatal dopaminergic denervation and longitudinal motor and cognitive outcomes in PD. Methods: We classified 476 patients with drug-naive PD who had undergone dopamine transporter imaging into three groups. They were selected according to a prior diagnosis of hypertension and use of DHPs and were matched using propensity scores: patients without hypertension (HTN-; n = 50) and patients with hypertension treated without DHP (HTN+/DHP-; n = 50) or with DHP (HTN+/DHP+; n = 50). Multiple linear regression and linear mixed model analyses were performed to determine intergroup differences in baseline dopamine transporter availability and longitudinal changes in the levodopa-equivalent dose, respectively. Using Kaplan-Meier analyses, we compared the risks of levodopa-induced dyskinesia, wearing off, and dementia-free survival during the 5.06 years of the mean follow-up period. The Cox regression model determined the independent effects of DHPs on dementia conversion. Results: Dopamine transporter availability in all striatal subregions was comparable between the HTN-, HTN+/DHP-, and HTN+/DHP+ groups. The risks of levodopa-induced dyskinesia and wearing off, as well as longitudinal changes in the levodopa-equivalent dose, did not differ between the groups. The HTN+/DHP+ group had a lower risk of developing dementia than the HTN+/DHP- (Bonferroni-corrected Plog-rank = 0.036) group. The use of DHP was independently associated with a lower risk of dementia conversion after controlling for other antihypertensive drugs and confounding factors (hazard ratio, 0.242; 95% confidence interval, 0.087-0.668; P = 0.006). Conclusions: DHPs may be associated with better long-term cognitive outcomes in hypertensive patients with PD. © 2023 International Parkinson and Movement Disorder Society. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Wiley-Liss | - |
dc.relation.isPartOf | MOVEMENT DISORDERS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antiparkinson Agents / adverse effects | - |
dc.subject.MESH | Cognition | - |
dc.subject.MESH | Dihydropyridines* / therapeutic use | - |
dc.subject.MESH | Dopamine Plasma Membrane Transport Proteins | - |
dc.subject.MESH | Dyskinesias* / drug therapy | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hypertension* / drug therapy | - |
dc.subject.MESH | Levodopa / adverse effects | - |
dc.subject.MESH | Parkinson Disease* / complications | - |
dc.subject.MESH | Parkinson Disease* / drug therapy | - |
dc.title | Effects of Dihydropyridines on the Motor and Cognitive Outcomes of Patients with Parkinson's Disease | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Neurology (신경과학교실) | - |
dc.contributor.googleauthor | Jin Ho Jung | - |
dc.contributor.googleauthor | Han Kyu Na | - |
dc.contributor.googleauthor | Seong Ho Jeong | - |
dc.contributor.googleauthor | Seok Jong Chung | - |
dc.contributor.googleauthor | Han Soo Yoo | - |
dc.contributor.googleauthor | Yang Hyun Lee | - |
dc.contributor.googleauthor | Kyoungwon Baik | - |
dc.contributor.googleauthor | Sang Jin Kim | - |
dc.contributor.googleauthor | Young H Sohn | - |
dc.contributor.googleauthor | Phil Hyu Lee | - |
dc.identifier.doi | 10.1002/mds.29367 | - |
dc.contributor.localId | A01982 | - |
dc.contributor.localId | A05367 | - |
dc.contributor.localId | A05714 | - |
dc.contributor.localId | A03270 | - |
dc.contributor.localId | A04666 | - |
dc.relation.journalcode | J02275 | - |
dc.identifier.eissn | 1531-8257 | - |
dc.identifier.pmid | 36825772 | - |
dc.identifier.url | https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.29367 | - |
dc.subject.keyword | Parkinson's disease | - |
dc.subject.keyword | calcium channel blocker | - |
dc.subject.keyword | dementia | - |
dc.subject.keyword | dihydropyridine | - |
dc.contributor.alternativeName | Sohn, Young Ho | - |
dc.contributor.affiliatedAuthor | 손영호 | - |
dc.contributor.affiliatedAuthor | 유한수 | - |
dc.contributor.affiliatedAuthor | 이양현 | - |
dc.contributor.affiliatedAuthor | 이필휴 | - |
dc.contributor.affiliatedAuthor | 정석종 | - |
dc.citation.volume | 38 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 843 | - |
dc.citation.endPage | 853 | - |
dc.identifier.bibliographicCitation | MOVEMENT DISORDERS, Vol.38(5) : 843-853, 2023-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.